Gail M. Farfel

Gail M. Farfel, Ph.D. has served as a director since April 2019. Dr. Farfel is CEO of ProMIS Neurosciences, a biotechnology company focused on the discovery and development of antibody therapeutics targeting misfolded proteins such as toxic oligomers, implicated in the development of neurodegenerative diseases. She served as the Executive Vice President and Chief Development Officer of Zogenix, Inc. from July 2015 until the acquisition of Zogenix by UCB Pharma in March 2022. At Zogenix, she oversaw Nonclinical and Clinical development, Regulatory Affairs, and Quality. Before joining Zogenix, Dr. Farfel was Chief Clinical and Regulatory Officer of Marinus Pharmaceuticals, a biopharma engaged in development for neurological disorders. Prior to her entry into the biotech space, Dr. Farfel served as Vice President and Therapeutic Area Head for Neuroscience at Novartis Pharmaceuticals Corporation, where she oversaw their portfolio of neurology and psychiatry products. Dr. Farfel began her career in pharmaceutical drug development at Pfizer Inc., where she worked in Clinical Development and Global Medical Affairs, directing programs through all stages of clinical development and regulatory submissions. Dr. Farfel is the author of over 50 scientific articles in the areas of neuropsychopharmacology and drug effects and is a Director on the Boards of Avrobio Inc, and the American Society for Experimental Neurotherapeutics. She graduated from The University of Chicago with a PhD in Neuropsychopharmacology, and is a director on the Medical and Biological Sciences Alumni Board.